Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease

Summary

The investigators have recently discovered a metabolic biomarker which predicts Parkinson's disease (PD) at the early stages in patients and in animal models. The aim of BIOPARK is to investigate how the biomarker evolves in advanced PD stage, when diagnosis confirmation is higher, an in de novo PD patients who come from a different geographical area than those of the publication (since it is known that the metabolome is largely influenced by lifestyle). They will also evaluate if the biomarker is able to distinguish patients with a parkinsonian syndrome often confused with parkinson's disease, i.e. Multiple System Atrophy (MSA).

Eligibility

Inclusion Criteria:

* Patients with de novo Parkinson's disease, without dopaminergic treatment
* Patients with advanced Parkinson's disease (\> 5years) with dopaminergic treatment
* Patients with multiple system atrophy

Exclusion Criteria:

* Patients with deep brain stimulation
* Other neurodegenerative diseases
* patients protected by french law (pregnant or lactating women, prisoners, ...)

Conditions2

Browse More Trials